Head and Neck Cancers

Head and Neck cancers are those that usually begin in the cells that line the moist, mucosal surfaces inside the head and neck such as the mouth, nose and throat. These cancers account for about 3% of all cancers, and it is estimated that 55,070 new cases were diagnosed in 2014 accompanied by 12,000 deaths (1). Patients receiving radiation treatment for head and neck cancers have a significant risk for oral complications. These can be severe and often lead to permanent tissue changes that put the patient at risk for serious chronic complications (2). Use of BIO 300 during radiation therapy for head and neck cancers could help decrease the incidence of mucositis, oral lesions, and salivary gland dysfunction greatly increasing patient quality of life. 

Clinical Program

A randomized Phase II trial evaluating BIO 300 in the prevention of oral mucositis and xerostomia is currently pending protocol approval.

Anticipated start date Q1 2017.

  1. Cancer Facts & Figures 2014. Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index.
  2. Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ® - National Cancer Institute. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/HealthProfessional/page15